Neurocrine Biosciences
NBIX
#1570
Rank
S$17.47 B
Marketcap
S$175.22
Share price
1.15%
Change (1 day)
-14.68%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2025 (TTM): S$5.61

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is S$5.49. In 2024 the company made an earnings per share (EPS) of S$4.30 an increase over its 2023 EPS that were of S$3.23.

EPS history for Neurocrine Biosciences from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)S$5.6130.49%
2024S$4.3033.07%
2023S$3.2357.76%
2022S$2.0569.47%
2021S$1.21-78.21%
2020S$5.55990%
2019S$0.5181.82%
2018S$0.28-113.5%
2017S-$2.080.62%
2016S-$2.0657.28%
2015S-$1.3125.61%
2014S-$1.0418.84%
2013S-$0.88-1085.71%
2012S$0.08912

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
S$2.19-60.09%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
S$1.72-68.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
S$26.12 376.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
S$0.03819-99.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
S-$2.58-147.10%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
S$2.18-60.32%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
S-$38.07-793.74%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
S$2.25-59.02%๐Ÿ‡ฌ๐Ÿ‡ง UK